Literature DB >> 8296777

Outbreaks in highly vaccinated populations: implications for studies of vaccine performance.

P E Fine1, E R Zell.   

Abstract

Most of the factors associated with the failure of a vaccination to provide protective immunity are not distributed uniformly or randomly within populations. This paper explores the extent to which a nonrandom distribution of vaccination failures and the selection of exceptional situations for investigation may influence estimates of vaccine performance. The authors show that outbreak investigations will tend to underestimate vaccination efficacy, and that the extent of underestimation will be related directly to the size of the epidemic triggering an investigation, the vaccination coverage in the community, and the extent of clustering of vaccination failures in the population; it will be related inversely to the size of and contact intensity within the investigated community. These potential sources of bias are not the only problems that arise in estimating vaccine efficacy, but they should be taken into consideration when analyzing and interpreting outbreak situations. The fact that outbreak investigations carried out within the United States during the past decade have provided estimates of measles vaccination efficacy on the order of 95% is consistent with a somewhat higher overall "true" efficacy of current vaccines and procedures in the total population. It is important to understand better the frequency, distribution, and risk factors for vaccination failures in populations.

Mesh:

Substances:

Year:  1994        PMID: 8296777     DOI: 10.1093/oxfordjournals.aje.a116937

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

1.  Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy.

Authors:  N J Gay; L M Hesketh; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

2.  Measles vaccination policy.

Authors:  B G Williams; F T Cutts; C Dye
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

3.  Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options.

Authors:  H R Babad; D J Nokes; N J Gay; E Miller; P Morgan-Capner; R M Anderson
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

4.  [Comparison of the efficacy of various strains of mumps vaccine: a school survey].

Authors:  L Toscani; M Batou; P Bouvier; A Schlaepfer
Journal:  Soz Praventivmed       Date:  1996

5.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

Review 6.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 7.  [Mumps epidemiology--worldwide].

Authors:  C Herzog
Journal:  Soz Praventivmed       Date:  1995

8.  Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment.

Authors:  Zhujiazi Zhang; Luodan Suo; Jingbin Pan; Dan Zhao; Li Lu
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

9.  Think globally, act locally: the role of local demographics and vaccination coverage in the dynamic response of measles infection to control.

Authors:  M J Ferrari; B T Grenfell; P M Strebel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

10.  Implications for registry-based vaccine effectiveness studies from an evaluation of an immunization registry: a cross-sectional study.

Authors:  Barbara E Mahon; Kimberly M Shea; Nancy N Dougherty; Anita M Loughlin
Journal:  BMC Public Health       Date:  2008-05-14       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.